Jacob S Young,Michael D Prados,Nicholas Butowski
Jacob S Young
Glioblastoma has been shown to have many different genetic mutations found both within and between tumor samples. Molecular testing and genomic sequencing has helped to classify diagnoses and clarify difficult to interpret histopathological...
Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients [0.03%]
多西他赛新辅助治疗乳腺癌患者的药代基因组学影响研究
Sarah Sim,Jonas Bergh,Mats Hellström et al.
Sarah Sim et al.
Aim: This study aimed to investigate the effect of CYP3A4 and CYP3A5 genotypes on clinical outcomes of docetaxel treatment. Patients & methods: ...
Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations [0.03%]
心血管药理基因组学标准不一致？证据级别对比分析
Jasmine A Luzum,Jason C Cheung
Jasmine A Luzum
Current guideline recommendations for pharmacogenetic testing for clopidogrel by the American Heart Association/American College of Cardiology (AHA/ACC) contradict the Clinical Pharmacogenetics Implementation Consortium and the US FDA. The ...
Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing [0.03%]
全外显子组测序在儿童急性淋巴细胞白血病患者中鉴定VIPN的遗传风险因素
Rachid Abaji,Francesco Ceppi,Swati Patel et al.
Rachid Abaji et al.
Aim: To identify genetic markers associated with vincristine-induced peripheral neuropathy (VIPN) in childhood acute lymphoblastic leukemia. Patients & me...
Late stent thrombosis in a patient with CYP2C19*3/*17 genotype and clopidogrel high on-treatment platelet reactivity [0.03%]
携带CYP2C19*3/*17基因型的高氯吡格雷抵抗患者的迟发性支架内血栓形成事件
Shirley Siang Ning Tan,Keng Tat Koh,Lee Len Tiong et al.
Shirley Siang Ning Tan et al.
Aim: Recurrent thrombotic events still occur despite dual antiplatelet therapy in patient's post percutaneous coronary intervention (PCI) could be attributed to high on-treatment platelet reactivity. ...
Case Reports
Pharmacogenomics. 2018 Oct;19(15):1151-1157. DOI:10.2217/pgs-2018-0082 2018
Cytochrome P450 genotype and aggressive behavior on selective serotonin reuptake inhibitors [0.03%]
细胞色素P450基因型与五羟色胺再摄取抑制剂的攻击性行为之间的关系
Corine Ekhart,Maja Matic,Agnes Kant et al.
Corine Ekhart et al.
Letter in reply to: Eikelenboom-Schieveld SJM, Fogleman JC. Letter to the Editor. Pharmcogenomics 19(14), 1095-1096 (2018) [ 1 ]. Regarding: Ekhart, Matic M, Kant A, van Puijenbroek E, van Schaik R. CYP450 genotype and aggressive behavior o...
Letter to the Editor [0.03%]
读者来信
Selma Jm Eikelenboom-Schieveld,James C Fogleman
Selma Jm Eikelenboom-Schieveld
Letter regarding: Ekhart C, Matic M, Kant A, van Puijenbroek E, Schaik RV. CYP450 genotype and aggressive behavior on selective serotonin reuptake inhibitors. Pharmacogenomics 18(7), 613-620 (2017) [ 1 ]. ...
Clinical and pharmacogenetics associated with recovery time from general anesthesia [0.03%]
与全身麻醉恢复时间相关的临床和药物基因组学研究
Shangchen Xie,Wenjuan Ma,Minxue Shen et al.
Shangchen Xie et al.
Aim: Delayed recovery from general anesthesia is a well-known complication that requires predictive tools and approaches. This study aimed to determine significant factors associated with postanesthesia recovery and to de...
Observational Study
Pharmacogenomics. 2018 Sep 1;19(14):1111-1123. DOI:10.2217/pgs-2018-0085 2018
Clinical implications of selective serotonin reuptake inhibitors-selective serotonin norepinephrine reuptake inhibitors pharmacogenetics during pregnancy and lactation [0.03%]
选择性5-羟色胺再摄取抑制剂和选择性5-羟色胺及去甲肾上腺素再摄取抑制剂药物基因组学在妊娠期和哺乳期的临床意义
Gideon Koren,Asher Ornoy
Gideon Koren
Depression occurs during pregnancy in 3.9-12.8% of the women. The different serotonin reuptake inhibitors (SRIs) are metabolized in the liver by CYP450 enzymes. CYP2D6 metabolizes paroxetine, fluoxetine, duloxetine and venlafaxine, while CY...
Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients [0.03%]
全面的ARA-C SNP评分可预测儿童急性髓系白血病患者白血病细胞内的ara-CTP水平
Abdelrahman H Elsayed,Xueyuan Cao,Kristine R Crews et al.
Abdelrahman H Elsayed et al.
Aim: Cytarabine (Ara-C), a mainstay of acute myeloid leukemia (AML) treatment, is a prodrug requiring activation to ara-CTP for its antileukemic activity. Aim of this study was to evaluate impact of genetic variants in th...